Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells

Blood

Volumn 89, Issue 12, 1997, Pages 4290-4298

  Higazi, Abd Al Roof ^a   Lavi, Ehud ^b   Bdeir, Khalil ^b   Ulrich, Anthony M ^b   Jamieson, Dara G ^b   Rader, Daniel J ^b   Usher, David C ^b   Kane, William ^b   Ganz, Tomas ^b   Cines, Douglas B ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFENSIN; LIPOPROTEIN A;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0030947598     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.12.4290     Document Type: Article

References (65)

1. Rader DJ, Hoeg JM, Brewer HB Jr: Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 120:1012, 1994
2. Rosenson RS: Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Arch Intern Med 156:1278, 1996
3. Schreiner PJ, Heiss G, Tyroler HA, Morrisett JD, Davis CE, Smith R: Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol 16:471, 1996
4. Jurgens G, Taddei-Peters WC, Koltringer P, Petek W, Chen Q, Greilberger J, Macomber PF, Butman BT, Stead AG, Ransom JH: Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 26:1841, 1995
5. Rath M, Niendorf A, Reblin T, Dietel M, Krebber H-J, Beisiegel U: Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9:579, 1989
6. Nachman RL, Gavish D, Azrolan N, Clarkson TB: Lipoprotein(a) in diet-induced atherosclerosis in nonhuman primates. Arterioscler Thromb 11:32, 1991
7. Jamieson DG, Usher DC, Rader DJ, Lavi E: Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. Am J Pathol 147:1567, 1995
8. Callow MJ, Verstuyft J, Tangirala R, Palinski W, Rubin EM: Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest 96:1639, 1995
9. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC: Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 370:460, 1994
10. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF: A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 339:301, 1989
11. Hajjar KA, Gavish D, Breslow JL, Nachman RL: Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339:303, 1989
12. Liu J, Harpel PC, Pannell R, Gurewich V: Lipoprotein(a): A kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator. Biochemistry 32:9694, 1993
13. Ezratty A, Simon DI, Loscalzo J: Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 32:4628, 1993
14. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM: Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 260:1655, 1993
15. Miyata M, Biro S, Kaieda H, Tanaka H: Lipoprotein (a) stimulates the proliferation of cultured arterial smooth muscle cells through two pathways. FEBS Lett 377:493, 1995
16. Jaujiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, Huttunen JK: Lipoprotein (a) and coronary heart disease risk: A nested case control study of the Helsinki Heart Study participants. Atherosclerosis 89:59, 1991
17. Ridker PM, Stampfer MJ, Hennekens CH: Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 273:1269, 1995
18. Haffner SM, Moss SE, Klein BE, Klein R: Lack of association between lipoprotein(a) concentrations and coronary heart disease mortality in diabetis: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Metabolism 41:194, 1992
19. Friedman GD, Klastsky AL, Siegelaub AB: The leukocyte count as a predictor of myocardial infarction. N Engl J Med 290:1275, 1974
20. Zalokar JB, Richard JL, Claude JR: Leukocyte count, smoking and myocardial infarction. N Engl J Med 304:465, 1981
21. Grimm RH, Neaton JD, Ludwig W: Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA 254:1932, 1985
22. Ensrud K, Grimm RH: The white blood cell count and risk for coronary heart disease. Am Heart J 124:207, 1992
23. Ernst K, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA: Leukocytes and the risk of ischemic diseases. JAMA 257:2318, 1987
24. De Labry LO, Campion EW, Glynn RJ, Vokomas PS: White blood cell count as a predictor of mortality: Results over 18 years from the Normative Aging Study. J Clin Epidemiol 43:153, 1990
25. Weijemberg MP, Feskens EJM, Kromhout D: White blood cell count and the risk of coronary heart disease and all cause mortality in elderly men. Arterioscler Thromb Vasc Biol 16:499, 1996
26. Grau AJ, Buggle F, Becher H, Werle E, Hacke W: The association of leukocyte count, fibrinogen and C-reactive protein with vascular disease risk factors and ischemic vascular diseases. Thromb Res 82:245, 1996
27. Morton KE, Gavaghan TP, Krilis SA, Daggard GE, Baron DW, Hickie JB, Chesteman CN: Coronary artery bypass graft failure - An autoimmune phenomenon? Lancet 2:1353, 1986
28. Valtonen V, Kuikka A, Syrjanen J: Thrombo-embolic complications in bacteremic infections. Eur Heart J 14:20, 1993 (suppl K)
29. Vaaralo O, Alfthan G, Jauhianinen M, Leirisalo-Repo M, Aho K, Palosuo T: Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythrematosus. Lancet 341:923, 1993
30. Kabakov AE, Tertov VV, Saenko VA, Poverenny AM, Orekhov AN: The atherogenic effect of lupus sera: Systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol 63:214, 1992
31. Benditt EP, Barrett T, McDougall JK: Virus in the etiology of atherosclerosis. Proc Natl Acad Sci USA 80:6386, 1983
32. Melnick JL, Petrie BL, Dreesman GR, Burek JM, McCollum CH, DeBakey ME: Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 2:544, 1983
33. Thomas DH, Wang S-P, Grayston T, Siscovick DS, Stewart DK, Kronmal RA, Weiss NS: Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 11:547, 1991
34. Thorn DH, Grayston JT, Siscovick DS, Wanf S-P, Weiss NS, Daling JR: Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 268:68, 1992
35. Kuo C, Shor A, Campbell LA, Fukashi H, Patton DL, Grayston JT: Demonstration of Chlamydiae pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 167:841, 1993
36. Kuo C, Gown AM, Benditt EP, Grayston JT: Detection of Chlamydia pneumoniae inaortic lesions of atherosclerosis by immunohistochemical stain. Arterioscler Thromb 12:1501, 1993
37. Melnick SL, Shahar E, Folsom AR, Grayston KT, Sorlie PD, Wang S-P: Past infection by Chlamydiae pneumiae Strain TWAR and asymptomatic carotid atherosclerosis. Am J Med 95:499, 1993
38. Ganz T, Selsted ME, Szklarek D, Harwig SSL, Daher K, Bainton DF, Lehrer RI: Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 1427:1435, 1985
39. Selsted ME, Harwig SSL, Ganz T, Schilling JW, Lehrer RI: Primary structures of three human neutrophil defensins. J Clin Invest 76:1436, 1985
40. Kagan BL, Ganz T, Lehrer RI: Defensins: A family of antimicrobial and cytotoxic peptides. Toxicology 87:131, 1994
41. Selsted ME, Harwig SSL: Determination of the disulfide array in the human defensin HNP-2. A covalently cyclized peptide. J Biol Chem 264:4003, 1989
42. Hill CP, Yee J, Selsted ME, Eisenberg D: Crystal structure of defensin HNP-3, an amphiphilic dimer: Mechanisms of membrane permeabilization. Science 251:1481, 1991
43. Harwig SS, Ganz T, Lehrer RI: Neutrophil defensins: Purification, characterization, and antimicrobial testing. Methods Enzymol 236:160, 1994
44. Panyutich AV, Panyutich EA, Krapivin VA, Baturevich EA, Ganz T: Plasma defensin concentrations are elevated in patients with sepsis or bacterial meningitis. J Lab Clin Med 122:202, 1993
45. Higazi AA-R, Barghouti II, Abu-Much R: Identification of an inhibitor of tissue-type plasminogen activator-mediated fibrinolysis in human neutrophils. J Biol Chem 270:9472, 1995
46. Higazi AA-R, Ganz T, Kariko K, Cines DB: Defensin modulates tPA and plasminogen binding to fibrin and endothelial cells. J Biol Chem 271:17650, 1996
47. Liu J, Harpel PC, Gurewich V: Fibrin-bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin. Biochemistry 33:2554, 1994
48. de Vos AM, Ultsch MH, Kelley RF, Padmanabhan K, Tulinsky A, Westbrook M, Kossiakoff AA: Crystal structure of the kringle 2 domain of tissue plasminogen activator at 2.4-A Resolution. Biochemistry 31:270, 1992
49. McClean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 300:132, 1987
50. Rader DJ, Mann WA, Cain W, Kraft H-G, Usher D, Zech LA, Hoeg JM, Davignon J, Lupien P, Grossman M, Wilson JM, Brewer HB Jr: The low density liprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 95:1403, 1995
51. Cines DB, Lyss AP, Reeber MJ, Bina M, DeHoratius R: Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus. J Clin Invest 73:611, 1984
52. Grobmeyer SR, Kuo A, Orishimo M, Okada SS, Cines DB, Barnathan ES: Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells. J Biol Chem 268:13291, 1993
53. Panyutich AV, Voitenok NN, Lehrer RI, Ganz T: An enzyme immunoassay for human defensin. J Immmunol Methods 141:149, 1991
54. Lafferty MA, Salamon AM, Usher DC: Immunochemistry of human Lp[a]: Chacterization of monoclonal antibodies that crossreact strongly with plasminogen. J Lipid Res 32:277, 1991
55. Park KS, Rifat S, Eck H, Adachi K, Surrey S, Poncz M: Biologic and biochemical properties of recombinant platelet factor 4 demonstrate identity with native protein. Blood 75:1290, 1990
56. Usher DC, Swanson C, Rader DJ, Kramer J, Brewer HB: A comparison of Lp(a) levels in fresh and frozen plasma using ELISAs with either anti-apo(a) or anti-apoB reporting antibodies. Chem Phys Lipids 67-68:243, 1994
57. Camejo G, Olofsson S-O, Lopez F, Carlsson P, Bondjers G: Identification of apo B-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans. Arteriosclerosis 368:377, 1988
58. Faber M: The human aorta: Sulfate-containing polyuronides and the depostion of cholesterol. Arch Pathol 48:342, 1949
59. Pekelharing HLM, Kleinveld HA, Duff PFCCM, Bouma BN, vanRijn HJM: Effect of lipoprotein (a) and LDL on plasminogen binding to extracellular matrix and on matrix-dependent plasminogen activation by tissue plasminogen activator. Thromb Haemost 75:497, 1996
60. Salonen E-M, Jauhiaianen M, Zardi L, Vaheri A, Ehnholm C: Lipoprotein (a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO J 8:4035, 1989
61. 2-macroglobulin receptor. FEBS Lett 325:271, 1993
62. Hofman SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Hammer RE: Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest 85:1542, 1990
63. Fless GM, Snyder ML: Polymorphic forms of Lp(a) with different structural and functional properties: Cold-induced self-association and binding to fibrin and lysine-Sepharose. Chem Phys Lipids 67-68:69, 1994
64. Niendorf A, Rath K, Wolf S, Peters S, Arps H, Beisiegel U, Dietel M: Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions of human aorta and coronary arteries. Virchows Arch A Pathol Anat Histopathol 417:105, 1990
65. Smith EB, Cochran S: Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) [Lp(a)]. Atherosclerosis 84:173, 1990